Lupin
BSE 500257
9 stories, newest first.
- U.S. FDA concludes Goa facility inspection, closes with Form-483 and one observation
- Lupin appoints Brian Savage as President, Chief Legal Officer
- Lupin schedules Q2 FY27 earnings call for November 4, 2026 at 18:00 hrs IST
- Board meeting on November 03, 2026 to consider and approve September quarter results
- ESG Rating of 70 for FY26 against 71 for FY25 under NSE Sustainability's independent assessment
- U.S. FDA approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL prefilled syringe
- Formoflo-G MDI launched in India, world's first fixed-dose triple combination drug for COPD management
- Philippines Arm Completes Buyback of 30,559 Shares, Becomes Step-Down Wholly Owned Subsidiary
- Tentative U.S. FDA Approval for Novel Apixaban Oral Suspension 1.25 mg/mL
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.